- Home
- CVAC
CVAC
CureVac N.V.
as 07-01-2025 3:34pm EST
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.
| Founded: | 2000 | Country: | Germany |
| Employees: | N/A | City: | N/A |
| Market Cap: | 764.4M | IPO Year: | 2020 |
| Target Price: | $6.83 | AVG Volume (30 days): | 2.1M |
| Analyst Decision: | Hold | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.87 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.37 - $5.72 | Next Earning Date: | 08-14-2025 |
| Revenue: | $566,039,775 | Revenue Growth: | 787.60% |
| Revenue Growth (this year): | -86.84% | Revenue Growth (next year): | 24.04% |
Latest CureVac N.V. News
CVAC Breaking Stock News: Dive into CVAC Ticker-Specific Updates for Smart Investing
ACCESS Newswire
8 days ago
CureVac Announces Voting Results of General Meeting
Zacks
12 days ago
CureVac Soars 41% in a Month on a $1.25B Buyout Offer From BioNTech
TipRanks
19 days ago
Oracle reports Q4 beat, BioNTech to acquire CureVac: Morning Buzz
BioPharma Dive
19 days ago
BioNTech buys mRNA, courtroom rival CureVac in all-stock deal
MT Newswires
19 days ago
Jefferies Downgrades CureVac to Hold From Buy, $5 Price Target
The Wall Street Journal
20 days ago
Stocks to Watch Recap: Boeing, Oracle, GE Aerospace, GameStop
MT Newswires
20 days ago
Top Midday Gainers
MT Newswires
20 days ago
Sector Update: Health Care
Compare CVAC vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CVAC CureVac N.V. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.